We further compared our 49-gene mUC signature with six established immunotherapy response predictors, including PD-L1 IHC and five tumor microenvironment (TME)-associated gene signatures: the IFN-γ signature (1), T-cell dysfunction signature (12), T-effector (tGE8) signature (2), T-cell–inflamed GEP (13), TIDE T-exhaust signature (12), and CD8T signature (14). This evidence concerns the gene IFNG and neoplasm.